Oxybutynin Tstransdermal Patch Suppliers & Bulk Manufacturers
Available Forms: transdermal patch
Available Strengths: 3.9 mg/24 hours
Reference Brands: Oxytrol, Oxytrol for Women(US & EU)
Category:
Urology
Oxybutynin transdermal patches deliver medication directly through the skin, blocking muscarinic receptors to reduce bladder muscle contractions. Benefits include steady drug levels, fewer side effects, improved patient compliance, reduced urgency and frequency, and better overall bladder control, supporting long-term management of overactive bladder with enhanced comfort.
Oxybutynin tstransdermal patch is available in transdermal patch
and strengths such as 3.9 mg/24 hours.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Oxybutynin tstransdermal patch is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Oxybutynin tstransdermal patch can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Oxybutynin transdermal patches, marketed as Oxytrol, are approved in the US by the FDA and in the EU via EMA for managing overactive bladder. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical and quality information, while the EMA ensures compliance with regional safety and manufacturing standards.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing